CONSERVATIVE THERAPY IN MYOCARDIAL INFARCTION: THE IMPACT OF GENETIC FACTORS

Abstract

Recently, myocardial infarction is a significant medical and social problem. Mortality in one year after infarction remains high, regardless the therapy with all recommended for the prognosis improvement medications. As one of probable reasons for adverse prognosis could be considered drug tolerance, related to genes polymorphism, responsible for pharmacokinetics and pharmacodynamics of the drugs. Current review summarizes some available at the moment literature data in the genes SLCO1B1, LIPC, CYP2C19, АСЕ, ADRB1 polymorphism influence on the effectiveness of myocardial infarction therapy, that might be useful for further scientific investigation or improvement of long term treatment of this disease by personalization of drug therapy.

Keywords

• genes polymorphism
• pharmacokinetics
• personalized medicine
• prognosis after myocardial infarction